Abstract
Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.
| Original language | English |
|---|---|
| Journal | PET Clinics |
| Volume | 12 |
| Issue number | 2 |
| Pages (from-to) | 243-255 |
| Number of pages | 13 |
| ISSN | 1556-8598 |
| DOIs | |
| Publication status | Published - Apr 2017 |
Keywords
- Animals
- Drug Evaluation, Preclinical/methods
- Gallium Radioisotopes
- Heterocyclic Compounds
- Humans
- Male
- Mice
- Positron Emission Tomography Computed Tomography/methods
- Positron-Emission Tomography/methods
- Prostatic Neoplasms/diagnostic imaging
- Radiopharmaceuticals
- Receptors, Urokinase Plasminogen Activator/metabolism
- Tomography, X-Ray Computed